___

• Manganiello V.Cyclic nucleotide phosphodiesterase 5 and sildenafil: promises realized. Mol Pharmacol. 2003; 63: 1209–1211.
• Kukreja RC, Salloum F, Das A, et al. Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. Vascul Pharmacol. 2005; 42: 219–232.
• Hotchkiss AK, Pyter LM, Gatien ML, et al. Aggressive behavior increases after termination of chronic silde- nafil treatment in mice. Physiol Behav. 2005; 83: 683–688.
• Canteros G, Rettori V, Genaro A, et al. Nitric oxide synthase content of hypothalamic explants: increase by norepinephrine and inactivated by NO and cGMP. Proc Natl Acad Sci. 1996; 93: 4246–4250.
• Yanık M, Vural H, Tutkun H, ve ark. The role of the arginine-nitric oxide pathway in the pathogenesis of bipolar affective disorder. Eur Arch Psychiatry Clin Neurosci. 2004; 254: 43–47.
• Moncada S, Palmer RM, Higgs EA. Nitric oxide: phys- iology,
• Pharmacol Rev. 1991; 43: 109–142. and
• pharmacology. 7. Yıldız F, Erden BF, Ulak G, ve ark. Antidepressant- like effect of 7-nitroindazole in the forced swimming test in rats. Psychopharmacology. 2000; 149: 41–44. 8. Eroğlu L, Cağlayan B. Anxiolytic and antidepressant properties of methylene blue in animal models. Pharmacol Res. 1997; 36: 381–385.
• Heiberg IL, Wegener G, Rosenberg R. Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats. Behav Brain Res. 2002; 134: 479–484.
• Suzuki E, Yagi G, Nakaki T, et al. Elevated plasma nitrate levels in depressive states. J Affect Disord. 2001; 63: 221–224.
• Chrapko WE, Jurasz P, Radomski MW, et al. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol Psychiatry. 2004; 56: 129–134.
• Bernstein HG, Stanarius A, Baumann B, et al. Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience. 1998; 83: 867–875.
• Karolewicz B, Szebeni K, Stockmeier CA, et al. Low nNOS protein in the locus coeruleus in major depres- sion. J Neurochem. 2004; 91: 1057–1066.
• Porsolt RD, Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature. 1977; 266: 730–32.
• Bourin M, Mocaer E, Porsolt R. Antidepressant-like activity of S 20098 (agomelatine) in the forced swim- ming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci. 2004; 29: 126–133.
• Schultheiss D, Muller SV, Nager W, et al. Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: a study with event-related brain potentials. World J Urol. 2001; 19: 46–50.
• Zhang R, Wang Y, Zhang L, et al. Sildenafil (Viagra) induces neurogenesis and promotes functional recov- ery after stroke in rats. Stroke. 2002; 33: 2675–2680. 18. Rutten K, Vente JD, Sik A, et al. The selective PDE5 inhibitor, sildenafil, improves object memory in Swiss mice and increases cGMP levels in hippocampal slices. Behav Brain Res. 2005; 164: 11–16.
• Heiberg IL, Wegener G, Rosenberg R. Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats. Behav Brain Res. 2002; 134: 479–484.
• Garthwaite J, Boulton CL. Nitric oxide signaling in the central nervous system. Annu Rev Physiol. 1995; 57: 683–706.
• Molina JA, Jimenez-Jimenez FJ, Orti-Pareja M, et al. The role of nitric oxide in neurodegeneration. Potential for pharmacological intervention. Drugs Aging. 1998; 12: 251–259.
• Simpson KL, Waterhouse BD, Lin RC. Differential expression of nitric oxide in serotonergic projection neurons: neurochemical identification of dorsal raphe inputs to rodent trigeminal somatosensory targets. J Comp Neurol. 2003 ;466: 495–512.
• Ramos AJ, Tagliaferro P, Lopez-Costa JJ, et al. Neuronal and inducible nitric oxide synthase immunoreactivity following serotonin depletion. Brain Res. 2002; 958: 112–121.
• Prasad HC, Zhu CB, McCauley JL, et al. Human sero- tonin transporter variants display altered sensitivity to protein kinase G and p38 mitogen-activated protein kinase. Proc Natl Acad Sci. 2005; 102: 11545–11550. 25. Zhu CB, Hewlett WA, Francis SH, et al. Stimulation of serotonin transport by the cyclic GMP phosphodi- esterase-5 inhibitor sildenafil. Eur J Pharmacol. 2004; 504: 1–6.
• Kiss JP. Role of nitric oxide in the regulation of monoaminergic neurotransmission. Brain Res Bull. 2000; 52: 459–466.
• Kaehler ST, Singewald N, Sinner C, et al. Nitric oxide modulates the release of serotonin in the rat hypo- thalamus. Brain Res. 1999; 835: 346–349.
• Wegener G, Volke V, Rosenberg R. Endogenous nitric oxide decreases hippocampal levels of serotonin and dopamine in vivo. Br J Pharmacol. 2000; 130: 575–580.
• Harkin A, Connor TJ, Burns MP, et al. Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test. Eur Neuropsychopharmacol. 2004; 14: 274–281.
• Joca SR, Guimaraes FS. Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces anti- depressant-like effects. Psychopharmacology. 2006; 185: 298–305.
• Wegener G, Volke V, Harvey BH, et al. Local, but not systemic, administration of serotonergic antidepres- sants decreases hippocampal nitric oxide synthase activity. Brain Res. 2003; 959: 128–134.